Perioperative Tyrosine Kinase Inhibitors for GIST: Standardâ€¦ or an Idea That Needs Further Investigation?  Conclusions While it is difficult to apply the traditional oncologic terms benign and malignant to GIST, risk stratification can identify patients who may potentially benefit from perioperative imatinib administration. Continued aggressive accrual to clinical trials will help us transform these various perioperative treatment strategies into standard practice for experienced multidisciplinary teams treating patients with this unique disease. 